Items where authors include "Bieber, T."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 10.

Article

Weidinger, S., Bieber, T., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (8 more authors) (2023) Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. British Journal of Dermatology, 189 (5). pp. 531-539. ISSN 0007-0963

Zuberbier, T. orcid.org/0000-0002-1466-8875, Abdul Latiff, A., Aggelidis, X. orcid.org/0000-0003-1715-3022 et al. (105 more authors) (2023) A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13 (9). e12299. ISSN 2045-7022

Bieber, T. orcid.org/0000-0002-8800-3817, Thyssen, J.P. orcid.org/0000-0003-3770-1743, Irvine, A.D. orcid.org/0000-0002-9048-2044 et al. (6 more authors) (2023) Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology, 48 (8). pp. 881-888. ISSN 0307-6938

Ring, J., Worm, M., Wollenberg, A. et al. (35 more authors) (2021) Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 35 (6). e362-e365. ISSN 0926-9959

Thyssen, J.P., Vestergaard, C., Barbarot, S. et al. (32 more authors) (2021) European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 35 (5). e308-e311. ISSN 0926-9959

Simpson, E.L., Sinclair, R., Forman, S. et al. (14 more authors) (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396 (10246). pp. 255-266. ISSN 0140-6736

Wollenberg, A., Flohr, C., Simon, D. et al. (30 more authors) (2020) European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 34 (6). e241-e242. ISSN 0926-9959

Thyssen, J.P., de Bruin-Weller, M.S., Paller, A.S. et al. (14 more authors) (2019) Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 33 (7). pp. 1224-1231. ISSN 0926-9959

Simpson, E.L., Bruin-Weller, M., Flohr, C. et al. (26 more authors) (2017) When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of The American Academy of Dermatology, 77 (4). pp. 623-633. ISSN 0190-9622

Simpson, E.L., Bieber, T., Guttman-Yassky, E. et al. (23 more authors) (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England Journal of Medicine. ISSN 0028-4793

This list was generated on Sat Mar 23 07:28:48 2024 GMT.